Protective effect of IL-18, but also the activation of NLRP3, have been previously reported in various mouse cancer models43,44 NLRP3 activation in DCs as well as IL-18 have been linked to better prognosis, to drive antitumor immunity and to enhance the efficacy of immunotherapies in different tumor models45,46. This evidence concerns the gene IL18 and neoplasm.